The Claim
In patients with atherosclerosis or diabetes who have not experienced a prior myocardial infarction or stroke and who have LDL cholesterol levels of at least 90 mg/dL, treatment with evolocumab 140 mg administered every 2 weeks reduces the risk of first major adverse cardiovascular events—including death from coronary heart disease, myocardial infarction, or ischemic stroke—by 25% over a period of 4.6 years compared to placebo, with a 5-year event rate of 6.2% in the evolocumab group versus 8.0% in the placebo group.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with diabetes or clogged arteries who haven’t had a heart attack or stroke yet, taking a drug called evolocumab every two weeks can lower their chance of having a first heart attack, stroke, or heart-related death by about 25% over nearly 5 years.
See the scientific wording
In patients with atherosclerosis or diabetes who have not had a prior myocardial infarction or stroke and who have LDL cholesterol levels of at least 90 mg/dL, treatment with evolocumab 140 mg every 2 weeks reduces the risk of first major adverse cardiovascular events, including death from coronary heart disease, myocardial infarction, or ischemic stroke, by 25% over 4.6 years compared to placebo, with a 5-year event rate of 6.2% versus 8.0%
What the research says
1 studyStudy: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
The study tested the exact same medicine, in the same kind of patients, and found it reduced heart problems by 25%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.